{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:24:14Z","timestamp":1720830254921},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,12]]},"DOI":"10.7759\/cureus.64427","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T19:04:20Z","timestamp":1720811060000},"source":"Crossref","is-referenced-by-count":0,"title":["Loperamide-Induced Torsades de Pointes"],"prefix":"10.7759","author":[{"given":"Binita","family":"Bhandari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Link","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.04.027","article-title":"Loperamide-induced torsades de pointes: a case series","volume":"53","author":"Katz KD","year":"2017","unstructured":"Katz KD, Cannon RD, Cook MD, et al.. Loperamide-induced torsades de pointes: a case series. J Emerg Med. 2017, 53:339-44. 10.1016\/j.jemermed.2017.04.027","journal-title":"J Emerg Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1885","article-title":"Loperamide trends in abuse and misuse over 13 years: 2002-2015","volume":"37","author":"Lasoff DR","year":"2017","unstructured":"Lasoff DR, Koh CH, Corbett B, Minns AB, Cantrell FL. Loperamide trends in abuse and misuse over 13 years: 2002-2015. Pharmacotherapy. 2017, 37:249-53. 10.1002\/phar.1885","journal-title":"Pharmacotherapy"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.11.003","article-title":"\"I just wanted to tell you that loperamide WILL WORK\": a web-based study of extra-medical use of loperamide","volume":"130","author":"Daniulaityte R","year":"2013","unstructured":"Daniulaityte R, Carlson R, Falck R, Cameron D, Perera S, Chen L, Sheth A. \"I just wanted to tell you that loperamide WILL WORK\": a web-based study of extra-medical use of loperamide. Drug Alcohol Depend. 2013, 130:241-4. 10.1016\/j.drugalcdep.2012.11.003","journal-title":"Drug Alcohol Depend"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2016.08.444","article-title":"Epidemiologic trends in loperamide abuse\u00a0and\u00a0misuse","volume":"69","author":"Vakkalanka JP","year":"2017","unstructured":"Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic trends in loperamide abuse\u00a0and\u00a0misuse. Ann Emerg Med. 2017, 69:73-8. 10.1016\/j.annemergmed.2016.08.444","journal-title":"Ann Emerg Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1449","article-title":"Loperamide: a readily available but dangerous opioid substitute","volume":"59","author":"White CM","year":"2019","unstructured":"White CM. Loperamide: a readily available but dangerous opioid substitute. J Clin Pharmacol. 2019, 59:1165-9. 10.1002\/jcph.1449","journal-title":"J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jce.14129","article-title":"Electrocardiographic changes in loperamide toxicity: case report and review of literature","volume":"30","author":"Teigeler T","year":"2019","unstructured":"Teigeler T, Stahura H, Alimohammad R, et al.. Electrocardiographic changes in loperamide toxicity: case report and review of literature. J Cardiovasc Electrophysiol. 2019, 30:2618-26. 10.1111\/jce.14129","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2016.11.011","article-title":"Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse","volume":"57","author":"Swank KA","year":"2017","unstructured":"Swank KA, Wu E, Kortepeter C, McAninch J, Levin RL. Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse. J Am Pharm Assoc (2003). 2017, 57:S63-7. 10.1016\/j.japh.2016.11.011","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12505","article-title":"Loperamide cardiotoxicity: \"A brief review\"","volume":"23","author":"Akel T","year":"2018","unstructured":"Akel T, Bekheit S. Loperamide cardiotoxicity: \"A brief review\". Ann Noninvasive Electrocardiol. 2018, 23:e12505. 10.1111\/anec.12505","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytz150","article-title":"Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report","volume":"3","author":"Cicci JD","year":"2019","unstructured":"Cicci JD, Jagielski SM, Clarke MM, Rayson RA, Cavender MA. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report. Eur Heart J Case Rep. 2019, 3:1-6. 10.1093\/ehjcr\/ytz150","journal-title":"Eur Heart J Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1026971","article-title":"Loperamide toxicokinetics: serum concentrations in the overdose setting","volume":"53","author":"Eggleston W","year":"2015","unstructured":"Eggleston W, Nacca N, Marraffa JM. Loperamide toxicokinetics: serum concentrations in the overdose setting. Clin Toxicol (Phila). 2015, 53:495-6. 10.3109\/15563650.2015.1026971","journal-title":"Clin Toxicol (Phila)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2017.04.008","article-title":"Clinical review: loperamide toxicity","volume":"70","author":"Wu PE","year":"2017","unstructured":"Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med. 2017, 70:245-52. 10.1016\/j.annemergmed.2017.04.008","journal-title":"Ann Emerg Med"},{"key":"ref12","unstructured":"FDA Drug Safety Communication. FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. (2018). Accessed: June 10, 2020: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-heart-pr...."},{"key":"ref13","unstructured":"FDA In Brief. FDA approves new packaging for brand-name over-the-counter loperamide to help curb abuse and misuse. (2019). Accessed: June 20, 2020: https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-approves-new-packaging-brand-name-over-counter-loperamide-hel...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/37853-loperamide-induced-torsades-de-pointes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T19:04:23Z","timestamp":1720811063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/37853-loperamide-induced-torsades-de-pointes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.64427","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}